In Phase C, participants will receive ABBV-744 and oral navitoclax. In Segment D, contributors will receive ABBV-744 and ruxolitinib. Contributors will acquire treatment until eventually disease progression or the contributors are unable to tolerate the study drugs. Doable new approaches to the prognosis and treatment of AML. (A) The identification https://abbv-744brd4inhibitorcanc13568.eedblog.com/31995928/the-smart-trick-of-abbv-744-preclinical-studies-and-results-that-nobody-is-discussing